Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Core Viewpoint - Scilex Holding Company announced the extension of the lock-up period for its Dividend Stock until April 14, 2025, as approved by the U.S. Bankruptcy Court for the Southern District of Texas, affecting shares previously distributed by Sorrento Therapeutics [1][5]. Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, and is also pursuing a joint venture with IPMC Company in neurodegenerative and cardiometabolic diseases [4][8]. - The company targets high unmet needs in the market with non-opioid therapies and aims to improve patient outcomes [4]. Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [4]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [4]. - Gloperba®, the first liquid oral version of colchicine for gout flare prophylaxis [4]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections to treat sciatica, which has completed Phase 3 studies [5][6]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completed Phase 2 trials [6]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [6]. Regulatory Status - SP-102 has received Fast Track status from the FDA, indicating its potential for expedited development [6]. - SP-103 has also been granted Fast Track status for low back pain [6]. Market Position - Scilex is headquartered in Palo Alto, California, and is positioned as a clinical late-stage specialty pharmaceutical company focusing on non-opioid pain therapies [7][8].